Table 2. Relationships between metastasis-free interval and clinicopathologic characteristics.
| Characteristic | Short MFI (n=133) No. (%) |
Intermediate MFI (n=135) No. (%) |
Long MFI (n=67) No. (%) |
p-value |
|---|---|---|---|---|
| Age at diagnosis of metastasis (yr) | < 0.001 | |||
| ≥ 50 | 43 (32.3) | 57 (42.2) | 41 (61.1) | |
| < 50 | 90 (67.7) | 78 (57.8) | 26 (38.9) | |
| Simplified metastatic location | 0.018 | |||
| Bone | 29 (24.1) | 32 (24.8) | 19 (34.5) | |
| Viscera | 60 (50.0) | 41 (31.7) | 15 (27.3) | |
| Both | 31 (25.9) | 56 (43.5) | 21 (38.2) | |
| Subtypes | < 0.001 | |||
| HR-positive/HER2-negative | 9 (16.7) | 27 (50.0) | 18 (64.3) | |
| HR-positive/HER2-positive | 8 (14.8) | 10 (18.5) | 1 (3.6) | |
| HR-negative/HER2-positive | 12 (22.2) | 10 (18.5) | 6 (21.4) | |
| Triple-negative | 25 (46.3) | 7 (13.0) | 3 (10.7) | |
| Tumor size (cm) | 0.019 | |||
| ≤ 2 | 26 (19.5) | 47 (34.8) | 20 (29.8) | |
| > 2 | 107 (80.5) | 88 (65.2) | 47 (70.2) | |
| Nodal status | 0.005 | |||
| Negative | 26 (19.8) | 40 (30.1) | 28 (41.7) | |
| Positive | 105 (81.1) | 93 (69.9) | 39 (58.3) | |
| Stage | < 0.001 | |||
| 0 | 0 | 0 | 2 (3.0) | |
| I | 9 (6.9) | 20 (14.8) | 11 (16.4) | |
| II | 49 (37.4) | 59 (44.3) | 37 (55.2) | |
| III | 73 (55.7) | 54 (40.9) | 17 (25.4) | |
| Histologic grade | < 0.001 | |||
| I/II | 68 (56.2) | 90 (70.9) | 50 (84.7) | |
| III | 53 (43.8) | 37 (29.1) | 9 (15.3) | |
| Ki-67 | 0.233 | |||
| Low ( < 20%) | 27 (67.5) | 35 (83.3) | 8 (80.0) | |
| High ( ≥ 20%) | 13 (32.5) | 7 (16.7) | 2 (20.0) |
MFI=metastasis-free interval; HR=hormone receptor; HER2=human epidermal growth factor receptor 2.